Exploring oligonucleotide-based silencing strategies to prevent anthracycline-induced cardiotoxicity

Authors

DOI:

https://doi.org/10.26754/jji-i3a.202613335

Abstract

Chemotherapy-induced cardiotoxicity is a major limitation of anthracycline-based treatments such as doxorubicin. Since TOP2B has been identified as a key mediator of DOXO-induced cardiotoxicity, this work explores and optimizes shRNA- and ASO-based silencing strategies targeting TOP2B. Preliminary results support the development of chemically modified ASOs with improved therapeutic potential.

Downloads

Download data is not yet available.

Downloads

Published

2026-07-17

Issue

Vol. 14 (2026): Actas de la XV Jornada de Jóvenes Investigadores e Investigadoras del I3A - 9 de junio de 2026

Section

Artículos (Ingeniería Biomédica)

License

Copyright (c) 2026 Carolina Gómez, Estíbaliz Fernández Carro, Vira Sharko, Ana Rosa Remacha, Clara Alcaine, Ángel Luis García Otín, Laura Ordovás Vidal, Jesús Ciriza Astrain

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Gomez Moreno, C., Fernández Carro, E., Sharko, V., Remacha, A. R., Alcaine, C., García Otín, Ángel L., Ordovás Vidal, L., & Ciriza Astrain, J. (2026). Exploring oligonucleotide-based silencing strategies to prevent anthracycline-induced cardiotoxicity. Jornada De Jóvenes Investigadores Del I3A, 14. https://doi.org/10.26754/jji-i3a.202613335